Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Diabetes Ther · 2021 · PMC7882235 · PMID 33586120

Europe PMC DOI

hedged sentences

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

did not reach statistical significancep = 0.14not close (p > 0.1)

HOMA2 IR was significantly decreased (2.1 ± 0.9 to 1.7 ± 0.5; p = 0.01) in the pioglitazone group, and the small change in the empagliflozin group did not reach statistical significance (2.4 ± 1.2 to 2.2 ± 1.1; p = 0.14).

also in 111,027 other papers

marginally significantno p-value reported

Compared to placebo, empagliflozin patients had a marginally significant improvement in hepatic steatosis, while no significant change was observed with pioglitazone.

also in 26,082 other papers

borderline significantno p-value reported

Results A borderline significant decrease in CAP score was observed with empagliflozin compared to placebo, mean difference: − 29.6 dB/m (− 39.5 to − 19.6) versus − 16.4 dB/m (− 25.0 to − 7.8), respectively; p = 0.05.

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.